<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Virtual US Symposium: Clinically-Relevant Tumor Models for Cancer Drug Discovery and Development

December 9th 2020 - 9am PST

Join our Virtual Symposium to learn more about using advanced, clinically-relevant models to accelerate oncology drug development. Explore the role of modeling clinical resistance when developing new anticancer agents, how to use tumor organoids to evaluate CAR-T cell therapies, the latest breakthroughs in humanized mouse models, and more.

WEBINAR: Efficacy and irAE Assessment Of Therapeutic Antibodies With Target Specific Knock-In Models

November 24th 2020 - 9am/4pm EST

Join Dr Hongjuan Zhang to learn how novel HuGEMM™ and HuCELL™ human knock-in models are used to assess human-specific immunotherapies. Explore the latest research applying these platforms to evaluating immune related toxicities, to accelerate immuno-oncology drug discovery programs.

NEW WHITE PAPER: Learn When and How to Use Tumor Organoids in Oncology Drug Discovery

Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms.

ON DEMAND WEBINAR: Shifting the Paradigm of Cancer Treatment: How Can Optical Imaging Help?

Join Dr Yinfei Yin to explore the benefits of optical imaging in preclinical oncology research with an emphasis on immunotherapy development. Learn how imaging improves the predictive power of preclinical studies, and allows a more efficient and cost-effective translation into the clinic. Key new imaging models for evaluating novel anticancer agents will also be discussed.

Keeping Your Projects Moving During the

COVID-19 Pandemic

Read the update from Dr. Jean-Pierre Wery, CEO on how we're balancing our operations while keeping our staff and facilities safe. Find out more about our current global capacity - with all China sites fully operational, and a Proxy SD system for EU/US affected areas

ON DEMAND WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research

Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies.

NEW PUBLICATION: Genomic Analysis of Clinical Chinese ccRCC Samples to Guide Patient Stratification

Explore whole-transcriptomic analysis of tumor and matched normal tissues from Chinese ccRCC patients, to investigate differences in expression profiles across Chinese and Caucasian populations. Discover how genomic analysis of clinical samples has the potential to guide patient stratification.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

November 10, 2020

SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?

Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized therapeutic combinations for KRAS-mutated cancers.

Read More

November 10, 2020

SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?

Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized...

Read More

November 6, 2020

In Vivo Imaging of Syngeneic Models for Immuno-Oncology Studies

Explore how different imaging modalities are used to monitor in vivo immuno-oncology (I/O)...

Read More

October 28, 2020

Thermoneutrality and Preclinical Obesity Models

Explore how to improve translatability of preclinical obesity research by using murine...

Read More

October 26, 2020

Applications and Benefits of Engineered Syngeneic Cell Lines

Explore the use and main benefits of engineered syngeneic cell lines for investigating drug...

Read More

October 21, 2020

Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist

Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our...

Read More

Upcoming Events


November 24, 2020

Efficacy and irAE Assessment Of Therapeutic Antibodies With Target Specific Knock-In Models

Virtual


December 1-3, 2020

PREDiCT: 9th Tumour Models London 

Virtual


December 9th 2020 - 9am PST

Clinically-Relevant Tumor Models for Cancer Drug Discovery and Development Virtual US Symposium

Virtual


December 15-18, 2020

4th Annual NASH Summit

Virtual